Abstract
Neurodegenerative diseases (NDs) have lagged behind in terms of therapeutic innovation compared to other chronic diseases. However, recent successful launches have allowed the commercialization of few disease-modifying therapies (DMTs) targeting NDs. Considering that promising therapies (e.g., sodium phenylbutyrate and taurursodiol, lecanemab) are launching in North America, this study aims to review Health Technology Assessments (HTA) on previous DMTs on NDs in Canada and provide learnings for upcoming DMTs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
